Gastroesophageal-junction Cancer Clinical Trials

23 recruitingLast updated: June 17, 2026

There are 23 actively recruiting gastroesophageal-junction cancer clinical trials across 38 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include New York, New York, United States, Houston, Texas, United States, London, United Kingdom. Updated daily from ClinicalTrials.gov.


Gastroesophageal-junction Cancer Trials at a Glance

23 actively recruiting trials for gastroesophageal-junction cancer are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Phase 2 with 13 trials, with the heaviest enrollment activity in New York, Houston, and London. Lead sponsors running gastroesophageal-junction cancer studies include AstraZeneca, Memorial Sloan Kettering Cancer Center, and Daiichi Sankyo.

Browse gastroesophageal-junction cancer trials by phase

Treatments under study

About Gastroesophageal-junction Cancer Clinical Trials

Looking for clinical trials for Gastroesophageal-junction Cancer? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastroesophageal-junction Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastroesophageal-junction Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting
Phase 2Phase 3

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Gastroesophageal-junction CancerEsophageal AdenocarcinomaMetastatic Gastric Cancer+1 more
Pfizer840 enrolled71 locationsNCT07392892
Recruiting
Phase 2

A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer

Gastric CancerGastroesophageal-junction Cancer
Memorial Sloan Kettering Cancer Center37 enrolled7 locationsNCT07631000
Recruiting

Registry for Esophageal and Gastroesophageal Junction Cancer

Esophageal CancerGastroesophageal-junction Cancer
Memorial Sloan Kettering Cancer Center50 enrolled1 locationNCT06558786
Recruiting
Phase 1

IKS014 in Advanced Solid Tumors That Express HER2

Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.165 enrolled13 locationsNCT05872295
Recruiting
Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Esophageal CancerGastric CancerGastroesophageal-junction Cancer+2 more
Washington University School of Medicine42 enrolled1 locationNCT05187182
Recruiting
Phase 1Phase 2

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Endometrial CancerAdvanced Solid TumorsMSI-H or dMMR Advanced Solid Tumors+4 more
Eikon Therapeutics160 enrolled10 locationsNCT07262619
Recruiting
Phase 1

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Not Applicable

Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer

Gastroesophageal-junction CancerStomach NeoplasmsEsophageal Neoplasms
Nurettin Şahin120 enrolled1 locationNCT07482566
Recruiting
Phase 3

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 3

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric CancerGastroesophageal-junction Cancer
AstraZeneca572 enrolled186 locationsNCT06346392
Recruiting
Phase 3

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Phase 2

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca224 enrolled52 locationsNCT06219941
Recruiting
Phase 2

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

Gastric CancerGastroesophageal-junction Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.200 enrolled2 locationsNCT07110571
Recruiting
Phase 1

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Triple-Negative Breast CancerGastric CancerGastroesophageal-junction Cancer+9 more
Dren Bio96 enrolled10 locationsNCT06999187
Recruiting
Phase 2

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Gastroesophageal-junction CancerMetastatic Gastric CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital32 enrolled1 locationNCT07315854
Recruiting
Phase 2

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust50 enrolled9 locationsNCT06250036
Recruiting
Phase 1Phase 2

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+5 more
Merus B.V.523 enrolled45 locationsNCT03526835
Recruiting
Not Applicable

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

Colorectal, CancerEsophageal CancerGastric Cancer+8 more
University of California, Davis300 enrolled1 locationNCT06101277
Recruiting
Phase 2

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Gastroesophageal-junction CancerGastroesophageal Junction AdenocarcinomaMetastatic Cancer+6 more
Fudan University55 enrolled1 locationNCT06121700